ubs rates csl

CSL - UBS rates the stock as Buy
BY BROKER NEWS - 20/08/2009

--------------------------------------------------------------------------------

The broker says the result was solid, with plasma growth particularly strong for the industry as a whole, as well as for the stock outlook. While swine flu vaccine was expected to lift FY10 profits, the company is set to spend it on research and development, UBS says.

If plasma performance is sustained over the next six months, the analysts expect the business to gradually re-rate to previous levels.

Target falls $1.67 to $42.18. Sector: Pharmaceuticals, Biotechnology and Life Sciences.

Target price is $42.18.Current Price is $33.12. Difference: $9.06 - (brackets indicate current price is over target). If CSL meets the UBS target it will return approximately 21% (excluding dividends, fees and charges - negative figures indicate an expected loss).

• Get More Commentary, Dicussion & Market Info. On -
CSL - CSL LIMITED ;